BioCentury | Sep 1, 2008
Strategy

Back to School: Adversity & acclimatization

The drug industry’s self-image is built around innovation, creativity and cleverness in science and technology. But this conceit is not matched by originality in business practices. This is exposed during times of adversity. Over the...
BioCentury | Jul 7, 2008
Finance

3Q Financial Markets Preview: Disquieting murmurs

Companies and investors looking for a quick end to their pain are unlikely to find much joy in the traditionally slow third quarter. And although some market watchers say the malaise could end in the...
BC Week In Review | Jun 23, 2008
Company News

Actimis Pharmaceuticals, Boehringer Ingelheim deal

Boehringer will acquire Actimis in a structured buyout tied to the development of Actimis’ lead compound, AP768 . The antagonist of chemoattractant receptor-homolog on Th2 cells ( CRTH2 ) is in Phase I testing for asthma. Boehringer will...
BioCentury | Jun 23, 2008
Strategy

Monetizing a slice at a time

One way to get a quicker return on investment, especially in an environment where the IPO market is closed, is to salami slice a company’s assets to monetize the ripest ones first. Thus, it would...
BC Extra | Jun 18, 2008
Company News

Boehringer Ingelheim to acquire Actimis

Boehringer Ingelheim (Ingelheim, Germany) said it will acquire Actimis (San Diego, Calif.) in a structured buyout tied to the development of Actimis' lead compound, AP768 . The antagonist of chemoattractant receptor-homolog on Th2 cells ( CRTH2 ) is...
Items per page:
1 - 5 of 5